866-945-0263 | enquiries@arrowheadpublishers.com

Press Releases

October 27, 2011

Drug Repositioning: New Technologies, Business Models & Strategies for Successful Development

Big Pharma’s 2012 colossal patent cliff looms. Thirteen blockbuster drugs are set to lose US patent protection; costing industry 70% in lost revenues. Furthermore, despite record R&D investment, biopharmaceutical productivity remains in decline.

Drug repositioning offers the possibility of breathing new life into pharmaceutical R&D. By recycling drug data, repositioning promises to boost production, accelerate and derisk R&D, and enhance product life-cycle management.

The promise of drug repositioning is now driving Big Pharma and Biotech to focus over 50% of its R&D activity into the approach. As the benefits of drug repositioning are being realized by industry; it is vital that stakeholders successfully navigate this challenging yet rewarding R&D paradigm.

Arrowhead Publishers has found that with around 2,000 Phase II and Phase III failed pipeline candidates typically sitting idle in a typical pharma drug library, drug repositioning may resurrect abandoned R&D programs. Success will recoup R&D costs and provide novel, high-value product life-cycle management.

Arrowhead has identified over 50 specialist drug repositioning companies offering unique screening technologies. It is essential that players adopt a multi-disciplined approach by forming collaborations with specialists to gain valid, fast results to unveil new commercial opportunities.

Key questions answered by this report:

  • Why is there a need for drug repositioning in the biopharmaceutical industry?
  • What are the major rewards offered by strategic drug repositioning?
  • What are the major challenges involved in this paradigm; and how can they be overcome?
  • Who are the key specialist players involved in the market and what business models are they utilizing?
  • What lessons can investors learn from established repositioned brands?
  • What products have recently gained FDA approval and what developmental pathway did they take?
  • How can players optimize strategic drug repositioning to maximize commercial success?
  • What are the key leading products and pipeline candidates in the market?
  • How much revenue will the leading products and key pipeline agents reach by 2016?
  • What financial rewards does the strategy provide?
  • What recommendations does Arrowhead provide for successful repositioning?
  • What does the future hold for the drug repositioning market?

For more information about this report, visit www.arrowheadpublishers.com or call 1-312-244-3703 or email us at This email address is being protected from spambots. You need JavaScript enabled to view it..

Contact Us

PO Box 96
Chanhassen, MN 55317 USA
866-945-0263
www.arrowheadpublishers.com
enquiries@arrowheadpublishers.com

Speaker Opportunities

If you are interested in speaking at one of Arrowhead's conferences or would like to suggest a conference theme for which you have particular expertise, we'd like to hear from you.

Sponsor/Exhibitor Opportunities

Arrowhead sponsorship and exhibitor levels are designed to give your organization the highest level of exposure and opportunity to market products and branding in an environment that is targeted toward facilitating professional networking. We can also build tailor-made packages that will meet your organization's marketing budget and goals. Arrowhead sponsorships are proven to help grow businesses through direct and targeted exposure to industry leaders and decision makers. To gain critical industry exposure via our sponsorship and exhibiting opportunities, please contact us.